What it is
GLOW is one vial holding three peptides at once: GHK-Cu 50 mg, BPC-157 10 mg, and TB-500 10 mg, 70 mg in total. It takes the Wolverine Stack (BPC-157 plus TB-500) and adds a copper peptide on top. The result is meant to do two things: heal tissue inside the body and improve how the skin and hair look on the outside.
The three parts:
GHK-Cu is a tiny peptide of three amino acids (glycine, histidine, lysine) bound to copper. It was first found in human blood plasma in 1973. It is the skin and hair half of the blend, and by far the biggest part by weight.
BPC-157 is a 15 amino acid peptide based on a protective protein found in stomach juice. It is the repair peptide that works close to where you inject it.
TB-500 is a lab-made copy of part of thymosin beta-4, a protein found in nearly all human cells. It travels through the whole body, so it does not matter where you inject it.
The healing pair here is double the amount in the standard Wolverine Stack, which has 5 mg of each. No study has tested these three together; the reasoning is that each one covers a different stage of repair.
It arrives as a dry powder. You mix it with bacteriostatic water and inject it just under the skin. The mixed liquid looks blue or green because of the copper. That is normal.
The copper matters. GHK-Cu on its own can sting and cause redness where you inject it. Users report the blend is much gentler than GHK-Cu alone, which is one reason people choose it.
None of these peptides is approved for human use. BPC-157 and TB-500 are banned in sport by WADA.
A fixed three-component co-formulation: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, 70 mg total peptide per vial at a 5:1:1 ratio. It is the Wolverine Stack (BPC-157 + TB-500) with GHK-Cu added, and carries double the healing peptide content of the standard Wolverine presentation (10 mg each versus 5 mg each).
GHK-Cu: glycyl-L-histidyl-L-lysine complexed with Cu(II), first isolated from human plasma in 1973. Modulates the expression of over 4,000 genes, delivers bioavailable copper for lysyl oxidase-mediated collagen cross-linking, drives collagen and elastin synthesis, dermal hydration and elasticity, photoprotection, and follicular enlargement. Dominant component at 71% of peptide mass.
BPC-157: pentadecapeptide fragment of a gastric juice protein, stable in gastric acid. Acts via VEGFR2 upregulation, angiogenesis, and growth factor signalling, amplifying existing repair signals at damaged tissue. Sub-30 minute half-life, so activity is greatest near the injection site.
TB-500: synthetic analogue of thymosin β4, a 43 amino acid actin-sequestering protein present in nearly all human cells. Promotes cell migration over long distances without binding the extracellular matrix, giving systemic distribution independent of injection site. Half-life approximately 10 days.
No published study has examined this three-peptide combination. The rationale is mechanistic: distinct, non-overlapping pathways addressing successive phases of tissue repair. The formulation also serves a tolerability function: GHK-Cu is cationic and triggers mast cell degranulation at the injection site, and users report substantially reduced reactions when it is co-formulated with BPC-157.
Supplied lyophilised; reconstituted with bacteriostatic water for subcutaneous administration. The solution carries a blue or green tint from the copper.
Regulatory: none of the components is FDA approved. BPC-157 and TB-500 are FDA Category 2 bulk drug substances and WADA prohibited under S0. GHK-Cu is widely used topically as Copper Tripeptide-1; injectable forms are restricted.
How it works
Think of healing as a building project with three jobs.
BPC-157 is the project manager. It makes damaged cells better at hearing the repair signals the body is already sending. That opens up blood vessels and grows new ones, so oxygen, nutrients, and immune cells reach the injured area. It also calms inflammation. Because it works by boosting an existing signal, it needs damaged tissue to act on. If nothing is injured, it has little to do.
TB-500 is the logistics team. Cells move using an internal scaffold made of a protein called actin. TB-500 holds a ready supply of actin building blocks so cells can move quickly to where they are needed. It is very small and does not get stuck in tissue, so it travels the whole body. That is why it does not matter where you inject it. It also helps grow blood vessels, releases a calming fragment as it breaks down, and can call in the body's own stem cells. It stays active for about 10 days, while BPC-157 is gone in under 30 minutes.
GHK-Cu is the materials supplier and quality inspector. Copper is needed by the enzyme that links collagen and elastin fibres into strong networks; without it, new collagen is weak. GHK-Cu delivers copper safely, without the harm loose copper would cause. It also tells skin cells to make more collagen, elastin, and moisture-holding molecules, and balances the enzymes that clear away old collagen. Lab studies show it can raise collagen production by up to 70%. At the gene level it nudges over 4,000 genes toward healthier patterns.
Your body makes GHK-Cu naturally, but levels fall with age: about 200 ng/mL at 20 years old, down to around 80 ng/mL by 60. Adding it back restores that signal.
All three grow blood vessels and all three calm inflammation, each in a different way. That overlap from different angles is the point of the blend.
Three mechanisms mapped to successive phases of the healing cascade.
Phase 1, repair signalling (BPC-157). Upregulates VEGFR2 expression, activating the Akt-eNOS pathway and nitric oxide production, producing vasodilation and angiogenesis. It increases receptor density rather than VEGF-A itself, so it amplifies endogenous repair signals and requires an injury signal to act on. Also activates FAK-paxillin for cell migration, upregulates growth hormone receptor expression in tendon fibroblasts via JAK2, and reduces COX-2 expression, IL-6, and TNF-alpha.
Phase 2, cell mobilisation (TB-500). Actin constitutes about 10% of total cellular protein. TB-500 binds actin monomers and prevents polymerisation, holding a reserve for rapid mobilisation during migration. It promotes migration without binding the extracellular matrix and, with its low molecular weight, distributes systemically. Also upregulates VEGF signalling for angiogenesis, releases the anti-inflammatory fragment Ac-SDKP on metabolism, and recruits endogenous stem and progenitor cells. Half-life approximately 10 days against BPC-157's sub-30 minutes.
Phase 3, tissue quality (GHK-Cu). Copper is the cofactor for lysyl oxidase, which cross-links collagen and elastin; without it, nascent collagen remains weak. GHK-Cu delivers bioavailable copper without free-copper toxicity. It stimulates fibroblast production of Type I and III collagen, elastin, and glycosaminoglycans (up to 70% collagen increase in vitro), and promotes TIMP synthesis to regulate metalloproteinases, balancing removal of damaged collagen against new deposition. At the transcriptional level it modulates over 4,000 genes toward repair and antioxidant defence while suppressing inflammatory and catabolic programmes. Endogenous plasma GHK-Cu falls from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60.
Convergence. All three are pro-angiogenic by different routes: VEGFR2 expression (BPC-157), VEGF signalling and endothelial behaviour (TB-500), VEGF release (GHK-Cu). All three are anti-inflammatory by different mechanisms. No synergy data exist; the combined effect could be additive, synergistic, or less than expected.
What it does
Each component does its own job.
BPC-157 stimulates collagen, reduces scar tissue, and speeds wound healing across skin, muscle, tendon, ligament, and more. Animal studies show it speeds healing of cut tendons, ligaments, and muscles.
TB-500 promotes collagen, reduces scarring, and protects, regenerates, and remodels damaged tissue, with wounds developing more mature, tightly organised collagen. In animal wound models it increased skin regrowth over the wound by 42% at day 4 and up to 61% at day 7. It also boosts antibody production and strengthens hair follicles.
GHK-Cu stimulates elastin and collagen, improves hydration, restores elasticity and helps reverse skin thinning, reduces fine lines, wrinkles, sun damage, and patchy dark pigmentation, protects against UV, and is anti-inflammatory and antioxidant. In a 12 week trial of 71 women it increased skin density and thickness and reduced fine lines and sagging. One study found it beat vitamin C and retinoic acid at raising collagen in sun-damaged skin. On hair, users and older guidance rate it equal to or better than 5% minoxidil, and it enlarges and strengthens follicles. It speeds wound closure by 40 to 50% in studies and reduces scarring.
Because TB-500 travels everywhere, the blend can support several injuries at once. Users report the blend causes fewer injection site reactions than GHK-Cu alone.
Component-level activity.
BPC-157: collagen synthesis; scar reduction; accelerated healing of transected tendons, ligaments, and muscles via fibroblast outgrowth, cell migration, and angiogenesis. Short half-life confines peak effect near the injection site.
TB-500: collagen production and organisation; reduced scarring; protection, regeneration, and remodelling of damaged tissue. Re-epithelialisation increased 42% at day 4 and up to 61% at day 7 in rat wound models, with improved contraction and collagen deposition. Increased antibody production; follicular stimulation. Systemic distribution supports multiple injury sites simultaneously.
GHK-Cu: elastin and collagen production; dermal hydration; restored elasticity and reversal of age-related thinning; reduction of fine lines, wrinkles, photodamage, hyperpigmentation; UV photoprotection; anti-inflammatory and antioxidant activity. A 12 week trial in 71 women showed increased skin density and thickness with reduced fine lines and sagging; a comparative study found GHK-Cu outperformed vitamin C and retinoic acid for collagen in photoaged skin. Wound closure accelerated 40 to 50% versus controls with reduced scar formation. Hair growth acceleration rated equal to or better than minoxidil 5%; follicular enlargement and strengthening. Gene expression modulation across over 4,000 genes.
Formulation effect: GHK-Cu is cationic and triggers mast cell degranulation; co-formulation with BPC-157 is reported to moderate the local histamine response. Anecdotal, not published.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Heals injured tissue: the BPC-157 and TB-500 pair speeds repair of tendons, ligaments, and muscles, and this vial holds double the amount in the standard Wolverine Stack.Animal or lab only
- Reduces the signs of ageing by improving skin health and appearance.Limited human data
- Regrows hair, strengthens and thickens follicles, and speeds hair growth.Animal or lab only
- Ideal for wound healing and reducing scar tissue.Animal or lab only
- From BPC-157: stimulates collagen, reduces scar tissue, and accelerates wound healing in skin, muscle, tendon, ligament, and more.Animal or lab only
- From TB-500: 42% faster skin regrowth over wounds at day 4 and up to 61% at day 7 in animal models, with more mature, tightly organised collagen.Animal or lab only
- From TB-500: travels the whole body, so several injuries can be treated at once from one injection site.Anecdotal
- From TB-500: boosts antibody production and stimulates hair follicles.Animal or lab only
- From GHK-Cu: stimulates elastin and collagen, improves hydration, restores elasticity, and helps reverse skin thinning.Limited human data
- From GHK-Cu: reduces fine lines, wrinkles, sun damage, and patchy dark pigmentation; protects against UV; anti-inflammatory and antioxidant.Animal or lab only
- From GHK-Cu: a 12 week trial of 71 women showed thicker, denser skin with fewer fine lines and less sagging.Human trials
- From GHK-Cu: outperformed vitamin C and retinoic acid for collagen in sun-damaged skin, and older guidance rates it more effective than most prescription retinols.Anecdotal
- From GHK-Cu: speeds wound closure by 40 to 50% and reduces scarring; can raise collagen production by up to 70% in lab studies.Animal or lab only
- From GHK-Cu: accelerates hair growth, rated equal to or better than 5% minoxidil, and enlarges follicles.Animal or lab only
- Users report less injection pain and redness than with GHK-Cu alone, because BPC-157 calms the copper reaction.Anecdotal
- One vial, one injection, one protocol instead of three separate ones.Anecdotal
- Musculoskeletal repair via the BPC-157 + TB-500 arm, at double the peptide content of the standard Wolverine Stack.Animal or lab only
- Reduction of ageing signs through improved skin health and appearance: the dermatological framing indication.Limited human data
- Hair regrowth, follicular strengthening and thickening, accelerated growth rate.Animal or lab only
- Wound healing and scar tissue reduction via tissue regeneration and GHK-Cu collagen organisation.Animal or lab only
- BPC-157 arm: collagen synthesis; scar reduction; accelerated healing of transected tendon, ligament, and muscle through fibroblast outgrowth, migration, and angiogenesis.Animal or lab only
- TB-500 arm: re-epithelialisation +42% at day 4 and up to +61% at day 7 in rat models; improved contraction and mature collagen architecture.Animal or lab only
- TB-500 arm: systemic distribution supporting multiple injury sites simultaneously.Anecdotal
- TB-500 arm: increased antibody production; follicular stimulation and strengthening.Animal or lab only
- GHK-Cu arm: elastin and collagen production; dermal hydration; restored elasticity with reversal of age-related thinning.Limited human data
- GHK-Cu arm: reduction of fine lines, wrinkles, photodamage, hyperpigmentation; UV photoprotection; anti-inflammatory and antioxidant activity.Animal or lab only
- GHK-Cu arm: 12 week trial, 71 women, increased skin density and thickness, reduced fine lines and sagging.Human trials
- GHK-Cu arm: outperformed vitamin C and retinoic acid for collagen in photoaged skin; claimed superiority over most prescription retinols is asserted without comparator.Anecdotal
- GHK-Cu arm: 40 to 50% acceleration of wound closure with reduced scarring; up to 70% collagen increase in vitro; modulation of over 4,000 genes.Animal or lab only
- GHK-Cu arm: hair growth acceleration rated equal to or better than minoxidil 5%; follicular enlargement.Animal or lab only
- Formulation benefit: co-formulation with BPC-157 moderates GHK-Cu-driven mast cell degranulation, giving substantially reduced injection site reactions versus standalone GHK-Cu (anecdotal).Anecdotal
- Convenience: single reconstitution, injection, and storage regime for three compounds.Anecdotal
What to expect
No study has tested the blend itself, so timelines come from the parts and from what users report.
Weeks 1 to 2: less pain and swelling, especially with a fresh injury. A few people notice smoother skin already, but most skin changes take longer.
Weeks 3 to 4: clear improvement in function for tendon and ligament injuries. People using it for skin start to notice better hydration and firmness.
Weeks 6 to 8: peak healing for muscle and joint injuries. Skin changes become more obvious, with fewer fine lines and better bounce. Some hair effects begin. Women in particular report firmer, better hydrated skin in this window.
Weeks 8 to 12: the copper peptide keeps remodelling collagen. People on longer anti-ageing runs report the most visible skin changes here.
Muscle injuries respond faster (2 to 4 weeks) than tendon injuries (4 to 8 weeks). Old or chronic injuries take longer (8 to 12 weeks) and are less predictable. Skin needs 8 or more weeks of steady use. Hair thickness is the slowest and least consistent, at 12 to 16 weeks or more.
Expect the liquid to look blue or green, and possibly a blue-green tinge at the injection spot. Both are normal. Some redness, swelling, or itching where you inject is the most common complaint, but users report it is milder than with GHK-Cu alone; some get no reaction at all. Mild tiredness, nausea at higher doses, headache, a metallic taste, and dizziness are less common and usually pass.
No clinical data exist for the combined blend; expectations derive from component pharmacokinetics and user reports.
Pharmacokinetics. BPC-157 half-life under 30 minutes, hepatic metabolism, renal excretion. TB-500 half-life approximately 10 days, allowing accumulation and sustained activity between doses. GHK-Cu serum half-life under one hour.
Reported timeline. Weeks 1 to 2: reduced pain and inflammation, particularly in acute injury; early texture changes in a minority. Weeks 3 to 4: significant functional improvement in tendon and ligament injury; early changes in skin hydration and firmness. Weeks 6 to 8: peak musculoskeletal healing; reduced fine lines and improved elasticity; onset of hair effects. Weeks 8 to 12: continued GHK-Cu-driven collagen remodelling, with the most visible skin changes reported in extended anti-ageing runs.
Muscle injury responds in 2 to 4 weeks, tendon in 4 to 8 weeks, chronic injury in 8 to 12 weeks with less predictable outcomes. Dermal effects require 8 or more weeks of consistent exposure. Hair thickness and quality changes are less consistent and slower, 12 to 16 weeks or more.
Tolerability. Injection site reactions (erythema, swelling, pruritus) from the cationic GHK-Cu component are the most common report, consistently less pronounced than standalone GHK-Cu; some individuals who welt on standalone GHK-Cu report no visible reaction on the blend. Blue or green solution tint and local discolouration are expected from copper. Less common: mild fatigue, nausea at higher doses, headache, metallic taste, dizziness. Effects are dose-dependent and transient.
Healing timelines track the Wolverine Stack, with improved skin quality as the additional layer.
Reconstitution and dosing
The vial holds 70 mg of peptide: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500. Mix it with 2 mL (200 units) of bacteriostatic water. Add the water slowly down the inside of the vial and swirl gently; do not shake. Mixed that way, 10 units on an insulin syringe gives 2.5 mg GHK-Cu, 500 mcg BPC-157, and 500 mcg TB-500 (3.5 mg of blended peptide). At 10 units a day the vial lasts 20 days.
Older guidance mixed the same vial with 2.5 mL (250 units), giving 280 mcg per unit and 1 to 2 mg of GHK-Cu per 5 to 10 unit dose. Either works; just know which one you mixed so your unit count means what you think it means.
The dose is 5 to 10 units. How often depends on your goal:
Healing (injury, post-surgery): once a day, every day, for 4 to 6 weeks. For surgery, start after the operation with your surgeon's approval.
Anti-ageing and skin: every other day, 3 to 4 times a week, for 8 to 16 weeks. The copper peptide needs steady exposure for visible skin change.
Maintenance and training recovery: twice a week, as needed.
Many users run daily for 6 to 12 weeks when doing both jobs at once, then take a 6 to 12 week break. Active healing runs of 4 to 8 weeks can stretch to 8 to 12 for deeper repair; a 4 to 6 week break between cycles is standard.
Inject just under the skin, in the belly, thigh, or upper arm. Any time of day; no need to be fasted. Be consistent. If you have one injury, inject near it so the BPC-157 lands where it is needed.
Reducing the sting. Inject slowly, let the solution warm to room temperature first, and rotate sites, never the same spot twice in a row. If it still stings, dilute the drawn dose with 20 or more units of extra bacteriostatic water (30 to 90 units if reacting strongly), then massage the site gently for about 60 seconds. If you cannot tolerate injections at all, the vial can be mixed into half an ounce to an ounce of thick moisturiser and used on the skin.
70 mg total peptide (GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg) reconstituted with 2 mL bacteriostatic water: 35 mg/mL, 350 mcg blended peptide per insulin unit. Per 10 units: 2.5 mg GHK-Cu, 500 mcg BPC-157, 500 mcg TB-500. Vial duration 20 days at 10 units daily.
Earlier guidance used 2.5 mL (28 mg/mL, 280 mcg/unit), so that 5 to 10 units delivered 1 to 2 mg GHK-Cu with 200 to 400 mcg each of BPC-157 and TB-500. The 2 mL figure is the current standard; the unit dose is unchanged, so per-arm exposure rises proportionally.
Context against component research. No dose-finding data exist for the blend. BPC-157 animal studies used 10 mcg/kg to 10 mg/kg. TB-500 animal doses translate to approximately 2 to 5 mg twice weekly in practice; 500 mcg daily is 3.5 mg/week, within that band but spread across seven administrations. GHK-Cu injectable studies used 0.5 to 2 mg daily; 2.5 mg per 10 units at 2 mL sits at the top of that range. The blend is a full-dose copper peptide protocol with modest healing peptide exposure relative to standalone use.
Protocols by goal. Healing focus (injury, post-surgical, tissue repair): 5 to 10 units once daily, subcutaneous, 4 to 6 weeks; post-surgical use starts post-operatively with surgeon approval. Anti-ageing focus (collagen, skin quality, gene expression): 5 to 10 units every other day, 3 to 4 times weekly, 8 to 16 weeks. Maintenance (tissue quality, training recovery): 5 to 10 units twice weekly, as needed. A combined skin-and-healing run of once daily for 6 to 12 weeks followed by a 6 to 12 week washout is also in practice. Standard active healing runs 4 to 8 weeks, extendable to 8 to 12; a 4 to 6 week break between cycles is standard.
Administration. Subcutaneous, abdomen, thigh, or upper arm; TB-500's systemic distribution makes site choice irrelevant for that arm, while proximity to injury maximises local BPC-157 concentration. No fasting; no timing constraint; no food interaction. Solution is blue-green from copper.
Reactivity mitigation. Slow injection, room-temperature solution, strict site rotation. If reacting: post-draw dilution with 20 or more units of bacteriostatic water (30 to 90 units for strong reactors), then 60 seconds of gentle massage. Topical salvage: add the reconstituted vial to half an ounce to an ounce of thick moisturiser.
Standard (healing), 70 mg vial
Mix with 2 mL (200 units) of bacteriostatic water.
35 mg/mL · 350 mcg per unit
Cycle: 4–6 weeks · Frequency: 1×/day, subcutaneous; any time of day; fasting not required
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 5 units (1.25 mg GHK-Cu, 250 mcg BPC-157, 250 mcg TB-500) | 5 units | 1×/day |
| Full | 10 units (2.5 mg GHK-Cu, 500 mcg BPC-157, 500 mcg TB-500) | 10 units | 1×/day |
Standard (anti-ageing), 70 mg vial
Mix with 2 mL (200 units) of bacteriostatic water.
35 mg/mL · 350 mcg per unit
Cycle: 8–16 weeks · Frequency: Every other day, 3–4×/week, subcutaneous
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 5 units (1.25 mg GHK-Cu, 250 mcg BPC-157, 250 mcg TB-500) | 5 units | every other day |
| Full | 10 units (2.5 mg GHK-Cu, 500 mcg BPC-157, 500 mcg TB-500) | 10 units | every other day |
Standard (maintenance), 70 mg vial
Mix with 2 mL (200 units) of bacteriostatic water.
35 mg/mL · 350 mcg per unit
Cycle: As needed · Frequency: 2×/week, subcutaneous
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 5 units (1.25 mg GHK-Cu, 250 mcg BPC-157, 250 mcg TB-500) | 5 units | 2×/week |
| Full | 10 units (2.5 mg GHK-Cu, 500 mcg BPC-157, 500 mcg TB-500) | 10 units | 2×/week |
Alternative protocols
Alternative protocols reflect older community practice and are kept for reference.
Alternative, 70 mg vial (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg)
Mix with 2.5 mL (250 units) of bacteriostatic water, giving 28 mg/mL — 280 mcg of blended peptide per insulin unit. To reduce copper-related injection reactions, add extra bacteriostatic water to the drawn dose before injecting: 20 or more units is one figure in use, and 30–90 units is another. Rotate the injection site every time, and massage the site for about 60 seconds afterwards.
28 mg/mL · 280 mcg per unit
Cycle: 6–12 weeks on, then a 6–12 week washout · Frequency: 1×/day, 7 days per week, subcutaneous; any time of day; fasting not required
| When | Dose | Draw | How often |
|---|---|---|---|
| Low end — 5 units (1 mg GHK-Cu plus 200 mcg each of BPC-157 and TB-500) | 1.4 mg | 5 units | 1×/day |
| Top of range — 10 units (2 mg GHK-Cu plus 400 mcg each of BPC-157 and TB-500) | 2.8 mg | 10 units | 1×/day |
70 mg of blend in 2 mL is 35 mg/mL, or 350 mcg per unit. Draw 5 units (0.05 mL) for 1.75 mg of blend.
- GHK-Cu1.25 mg
- BPC-157250 mcg
- TB-500250 mcg
Who should avoid it
- Anyone with an active cancer or tumour. All three peptides help new blood vessels grow, each in a different way, and that could in theory feed a tumour's blood supply. The standalone BPC-157 and TB-500 pages carry the same exclusion, and the TB-500 page extends it to cancer treatment and cancer in the family.
- Anyone with a history of cancer should talk to their oncologist before using it.
- Anyone with a known allergy to BPC-157, TB-500, thymosin peptides, or copper. The standalone BPC-157 page adds that anyone with a protein allergy should be careful, because BPC-157 is itself a protein.
- Anyone with Wilson's disease, an inherited condition where copper builds up in the body. GHK-Cu delivers copper.
- Anyone pregnant or breastfeeding. There is no safety data for any of the three components, and the standalone BPC-157 page says it is toxic to a developing baby.
- Anyone with liver or kidney problems should be cautious. The standalone BPC-157 page lists chronic kidney disease as a full exclusion, because the peptide puts extra strain on those organs.
- Anyone with a severe heart or circulation condition should be cautious. The standalone BPC-157 page notes it can raise blood pressure; the standalone TB-500 page excludes anyone being treated for a heart or circulation condition, and anyone with a blood clotting disorder affecting the face.
- Anyone with an autoimmune condition should be cautious. Two of the three component pages exclude autoimmune disease outright because the peptides stimulate the immune system, and TB-500 is claimed to boost antibody production. Treat the component exclusions as the ones that count.
- Anyone taking immunosuppressant medicines.
- Anyone with an active infection, because copper can encourage bacteria to grow.
- Copper reactivity. For some people GHK-Cu stings badly and causes a strong reaction where it is injected — redness, swelling, bruising, pain, and a knot under the skin lasting several days. It is not universal. If you get pain or an aggressive reaction, you can safely assume you will not react well to copper peptides in any form. Low ceruloplasmin (the blood protein that controls loose copper), already inflamed skin or small blood vessels, and low zinc or high iron all make it more likely.
- Watch for signs of copper toxicity: headache, fever, passing out, nausea, vomiting, vomiting blood, diarrhoea, black stool, abdominal cramps, brown ring-shaped markings in the eyes, yellowing of the skin or eyes, anxiety, irritability, trouble focusing, and low mood. In the most serious cases it can affect the kidneys, liver, heart, and brain. At 1 to 2 mg of GHK-Cu daily, copper toxicity is not a practical concern.
- Medicines: the data on NSAIDs (common painkillers such as ibuprofen) and BPC-157 is mixed. Some research says BPC-157 protects the gut from NSAID damage; other research suggests NSAIDs may get in the way of repair. No other drug interactions are established, because human research is limited.
- Athletes: BPC-157 and TB-500 are banned by WADA. None of the three is approved for human use.
- Because all three peptides sit in one vial at a fixed ratio, you cannot lower or drop one. If any warning above rules out one component, it rules out this blend.
- Active malignancy or tumours — contraindicated. All three arms are pro-angiogenic through distinct pathways (BPC-157 via VEGFR2 upregulation, TB-500 via VEGF signalling and endothelial behaviour, GHK-Cu via VEGF release), with theoretical support of tumour vascularisation. The standalone TB-500 page extends the exclusion to ongoing oncological treatment and family history; in a fixed blend the strictest exclusion governs.
- History of malignancy — oncologist consultation before use.
- Known hypersensitivity to BPC-157, TB-500, thymosin peptides, or copper. The standalone BPC-157 page adds polypeptide hypersensitivity generally.
- Wilson's disease — contraindicated. GHK-Cu is a copper delivery vehicle.
- Pregnancy and lactation — no safety data for any component; the standalone BPC-157 page describes fetotoxicity as an absolute contraindication.
- Hepatic or renal impairment — caution; chronic kidney disease is a full exclusion on the standalone BPC-157 page owing to clearance burden.
- Severe cardiovascular disease — caution. BPC-157 carries an NO-mediated pressor response; the standalone TB-500 page excludes ongoing cardiovascular treatment and facial blood clotting disorders.
- Autoimmune disease — caution for the blend, and an outright exclusion on the standalone BPC-157 and TB-500 pages given immunostimulatory and immunomodulatory activity, with TB-500 additionally claimed to increase antibody production. The component exclusions govern.
- Immunosuppressant medication — caution.
- Active infection — caution; copper can stimulate bacterial growth.
- Copper reactivity as the dominant tolerability constraint. GHK-Cu is cationic and triggers mast cell degranulation with local histamine release; ISRs comprise erythema, swelling, bruising, pain, and subcutaneous nodules persisting several days. Incidence is bimodal. A markedly painful injection or aggressive ISR indicates parenteral copper peptide intolerance in any form. Predictors: low baseline ceruloplasmin, pre-existing inflammation of the skin barrier or microcirculation, trace metal imbalance such as low zinc or high iron; mechanism given is transient dissociation of free copper from GHK with local oxidative activity.
- Copper toxicity presentation, from the standalone GHK-Cu page: headache, fever, syncope, nausea, vomiting, haematemesis, diarrhoea, melaena, abdominal cramps, Kayser-Fleischer-type markings, jaundice; neuropsychiatric features of anxiety, irritability, impaired concentration, depression, mood lability; severe cases with renal, hepatic, cardiac, and cerebral damage. The lethal dose is estimated at approximately 21,000 mg for a 70 kg human, and toxicity is not a practical concern at 1 to 2 mg daily.
- NSAIDs — mixed data with BPC-157: some research shows BPC-157 counteracts NSAID-induced gut damage, other research suggests NSAIDs may interfere with regenerative mechanisms. No other well-established interactions for the combination given limited human research.
- Regulatory: BPC-157 and TB-500 are FDA Category 2 bulk drug substances and WADA-prohibited under S0; GHK-Cu injectable forms are restricted. None is approved for human use.
- The fixed 5:1:1 ratio removes independent titration. A contraindication to any arm is a contraindication to the vial.
Side effects
- Most common: a reaction where you inject — redness, swelling, itching, tenderness, lumps, and/or bruising. This comes mainly from the GHK-Cu, and users report it is milder in the blend than with GHK-Cu on its own.
- Copper reactivity: injection pain ranging from a pinch to a bullet ant sting, and a knot under the skin lasting several days. Not everyone gets it.
- A blue or green tinge at the injection site. This comes from the copper and is normal.
- Mild tiredness or sluggishness.
- Less common: nausea (especially at higher doses), headache, a metallic taste from the copper, and dizziness.
- From the standalone GHK-Cu page: a histamine flare-up that looks like hives.
- From the standalone BPC-157 page: uncommon nausea, diarrhoea, appetite changes, gas or bloating, dizziness, and headaches.
- From the standalone TB-500 page: dizziness, headaches, tiredness, nausea, muscle pain, rarely flu-like symptoms, bloating if you have irritable bowel syndrome, and muscle spasms or odd contractions if the dose is too high.
- Signs of an allergic reaction: swelling, difficulty breathing, skin rash, hot flushes, facial swelling, itching, or heavy sweating. Stop and seek medical help if these appear.
- Most side effects are dose-dependent and temporary, and fade as the body adapts.
- Reducing the sting: inject slowly, let the solution warm to room temperature first, and rotate injection sites every time — never the same spot twice in a row. You can also dilute the drawn dose with extra bacteriostatic water (20 or more units in one section of the older guidance, 30 to 90 units in another; use the larger figure if you are reacting) and massage the site gently for about 60 seconds afterwards.
- What the research says: in animals BPC-157 showed no harm up to 20 mg/kg, and two healthy adults given IV infusions up to 20 mg had no problems — but two people does not establish safety. Thymosin beta-4 was safe and well tolerated in human trials, with no significant effects in rodents up to 100 mg/kg. GHK-Cu has decades of safe topical use; injectable data is limited.
- Injection site reaction — erythema, swelling, pruritus, tenderness, nodules, and/or bruising — is the most common report, driven by GHK-Cu-induced mast cell degranulation. Users consistently report it is less pronounced in the blend than with standalone GHK-Cu, plausibly because BPC-157 suppresses COX-2 expression and inflammatory cytokines including IL-6 and TNF-alpha. This is an anecdotal observation, not a published finding.
- Copper reactivity: variable injection pain and ISRs with subcutaneous nodules persisting several days.
- Blue or green discolouration at the injection site — copper, normal.
- Mild fatigue or lethargy.
- Less common: nausea (dose-related), headache, metallic taste from copper, dizziness.
- From the standalone GHK-Cu page: histamine flare resembling urticaria.
- From the standalone BPC-157 page: infrequent and predominantly gastrointestinal — nausea, diarrhoea, appetite change, flatulence and bloating — plus dizziness consistent with NO-mediated vasodilation and headache.
- From the standalone TB-500 page: dizziness, headache, fatigue, nausea, myalgia; rare flu-like symptoms; bloating in irritable bowel syndrome; muscle spasm or altered contraction from actin overstimulation at excessive doses.
- Hypersensitivity: swelling, dyspnoea, rash, hot flushes, facial oedema, pruritus, profuse sweating — discontinue and seek medical attention.
- Most effects are dose-dependent and transient.
- Mitigation: slow injection, solution warmed to room temperature, daily site rotation. Post-draw dilution with additional bacteriostatic water (20 or more units is one figure in use, 30–90 units another; the larger range is the reactivity countermeasure) and 60 seconds of gentle post-injection massage. Note that 30–90 units added to a 5–10 unit dose raises injected volume up to nineteenfold, which has not been evaluated.
- Published safety, component-level: BPC-157 showed no significant adverse effects or toxicity up to 20 mg/kg in animal hepatic, renal, mutagenic, and teratogenic assessments; one human study infused two healthy adults IV up to 20 mg without adverse events. Thymosin beta-4 was safe and well tolerated in Phase 1 volunteers, with no significant adverse effects in rodents up to 100 mg/kg. GHK-Cu has an established topical safety record; injectable data is limited, with an estimated lethal dose of approximately 21,000 mg for a 70 kg human.
What the evidence shows
No published study has tested GLOW as a combined product, and no study has looked at whether the three peptides work better together than apart. To be clear, the combined effect could be additive, better than additive, or less than expected. Everything below is about the components on their own.
BPC-157. A 2025 systematic review (Vasireddi et al., 2025) looked at 36 studies in sports medicine. 35 were in animals and only 1 was in humans. It found effects on blood vessel growth, cell movement, and tissue protection, and no acute toxicity in any organ at doses from 6 mcg/kg to 20 mg/kg in animals. A separate review (McGuire et al., 2025) called the repair effects robust but described human data as "exceedingly sparse" and said the compound should be treated as investigational.
TB-500. Malinda et al. (1999) showed thymosin beta-4 sped up skin regrowth over rat wounds by 42% at day 4 and up to 61% at day 7, with better wound contraction and collagen laydown. Bock-Marquette et al. (2004) showed it helps heart cells move, survive, and repair. Two human studies, Ruff et al. (2010) and Wang et al. (2021), found it safe and well tolerated in healthy volunteers.
GHK-Cu. Pickart and Margolina (2018) reviewed its effect on gene expression, finding it shifts over 4,000 genes toward healthier patterns at very low concentrations. Maquart et al. (1993) showed it increased collagen in rat wounds in a dose-dependent way. Finkley et al. (2005) ran a 12 week trial in 71 women and found thicker, denser skin with fewer fine lines and less sagging from a daily GHK-Cu face cream. Abdulghani et al. (1998) found GHK-Cu cream beat vitamin C and retinoic acid at building collagen in sun-damaged skin. Note that the human skin trials used cream, not injections.
The bottom line: strong animal data for the two repair peptides, real human skin data for GHK-Cu applied topically, safety-only human data for TB-500, and almost no human data for BPC-157.
No published study has examined the combined blend, and no synergy data exist. The rationale is mechanistic: BPC-157 establishes blood supply via VEGFR2 upregulation and Akt-eNOS signalling, TB-500 mobilises cells via actin sequestration, and GHK-Cu supplies copper for lysyl oxidase cross-linking plus gene expression modulation. The combined effect could be additive, synergistic, or less than expected.
BPC-157. Vasireddi et al. (2025), a systematic review in HSS Journal of 36 studies in sports medicine — 35 preclinical, 1 clinical — confirmed angiogenic, migratory, and cytoprotective effects with no acute toxicity across organ systems at 6 mcg/kg to 20 mg/kg in animal models; no study has assessed human safety. McGuire et al. (2025), a narrative review in Current Reviews in Musculoskeletal Medicine, found robust regenerative and cytoprotective preclinical effects but described human data as "exceedingly sparse" and the compound as investigational. Mechanistic support comes from VEGFR2 upregulation (Hsieh et al., 2017), tendon outgrowth, survival, and migration (Chang et al., 2011), and soft tissue healing (Gwyer et al., 2019).
TB-500. Malinda et al. (1999) in Journal of Investigative Dermatology: thymosin beta-4 increased re-epithelialisation by 42% at day 4 and up to 61% at day 7 in rat wounds, with improved contraction and collagen deposition, and stimulated keratinocyte migration 2 to 3 fold at concentrations as low as 10 picograms. Bock-Marquette et al. (2004) in Nature: activation of integrin-linked kinase with cardiac cell migration, survival, and repair. Human pharmacokinetics: Ruff et al. (2010) showed IV thymosin beta-4 safe and well tolerated in healthy volunteers; Wang et al. (2021) confirmed single and multiple dose safety in healthy Chinese volunteers.
GHK-Cu. Pickart and Margolina (2018) in International Journal of Molecular Sciences: modulation of over 4,000 human genes toward healthier patterns, affecting antioxidant defence, anti-inflammatory response, and DNA repair at picomolar to nanomolar concentrations. Maquart et al. (1993) in Journal of Clinical Investigation: concentration-dependent increase in collagen and glycosaminoglycan content in rat wounds, with collagen synthesis stimulation approximately twice that of noncollagen proteins. Finkley et al. (2005): 12 week trial, 71 women, significant improvement in skin density and thickness with reduced fine lines and sagging from daily facial cream. Abdulghani et al. (1998): GHK-Cu cream outperformed vitamin C and retinoic acid for collagen in photoaged skin. Laboratory work shows collagen production increases of up to 70%, and 40 to 50% acceleration of wound closure versus controls.
The human evidence for GHK-Cu is topical; extrapolation to subcutaneous dosing is inferential.
User reports
From public forums
These reports come from users, not studies, and carry less weight than published research.
Healing. Users report healing timelines similar to the two-peptide BPC-157 + TB-500 combination, with better skin quality as a bonus. Weeks 1 to 2: less pain and swelling, especially with fresh injuries. Weeks 3 to 4: clear functional gains for tendon and ligament problems, and early changes in skin hydration and firmness. Weeks 6 to 8: peak healing for muscle and joint injuries, more visible skin changes, and some early hair effects. Weeks 8 to 12: continued collagen remodelling, with the most visible skin changes for people running longer anti-ageing cycles. Muscle injuries tend to respond in 2 to 4 weeks, tendons in 4 to 8, and old or chronic injuries in 8 to 12, with less predictable results.
Skin and hair. Women in particular report firmer, better-hydrated skin and fewer fine lines after 6 to 8 weeks of consistent use. Hair thickness improvements are reported by some, but are less consistent and take 12 to 16 weeks or more.
Injection reactions. The most common complaint is the histamine reaction from the copper peptide, but users consistently say it is milder in the blend than with GHK-Cu alone. Some people who got significant redness and welts from standalone GHK-Cu get no visible reaction at all from the blend. The blue or green tint of the solution is normal.
How people use it. Most mix with 2 mL of bacteriostatic water and inject 5 to 10 units daily or every other day. Injury recovery users go daily for 4 to 6 weeks; skin and anti-ageing users go every other day for 8 to 16 weeks. Some run both at once.
Aggregated anecdotal reports; not published data.
Healing. Timelines track the BPC-157 + TB-500 combination alone, with improved skin quality as the differentiator. Weeks 1 to 2: reduced pain and inflammation in acute injury, occasional early texture change. Weeks 3 to 4: significant functional improvement in tendon and ligament injury; early hydration and firmness changes. Weeks 6 to 8: peak musculoskeletal results, more visible reduction in fine lines and improved elasticity, initial hair effects. Weeks 8 to 12: ongoing collagen remodelling from the GHK-Cu arm, with the most visible dermal change in longer anti-ageing protocols. Muscle responds in 2 to 4 weeks, tendon in 4 to 8, chronic lesions in 8 to 12 with less predictable outcomes. Dermal effects require consistent exposure over 8 or more weeks.
Skin and hair. Firmness, hydration, and fine-line reduction are reported most often by women after 6 to 8 weeks. Hair thickness and quality gains are less consistent and require 12 to 16 weeks or longer.
Injection site reactions. The GHK-Cu histamine reaction is the leading adverse report, consistently described as attenuated relative to standalone GHK-Cu; individuals who developed marked erythema and wheals on the standalone product report no visible reaction on the blend. The blue-green tint is expected.
Protocols in practice. Reconstitution with 2 mL bacteriostatic water; 5 to 10 units daily or every other day. Injury focus: daily for 4 to 6 weeks. Anti-ageing focus: every other day for 8 to 16 weeks. Concurrent dual-purpose use is common.
Pharmacokinetic context for the timelines. BPC-157 half-life is under 30 minutes with hepatic metabolism and renal excretion, so it acts locally; TB-500 half-life is approximately 10 days, allowing accumulation between doses; GHK-Cu serum half-life is under one hour.
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Suggested for telomere repair, DNA integrity, and longevity — the ageing side of the protocol rather than the skin side.
Telomere maintenance, DNA integrity, longevity. Complementary axis — cellular senescence rather than matrix remodelling.
Suggested to stimulate collagen, help tissue recovery, and increase growth hormone output. No interaction concerns, but growth hormone peptides need to be taken fasted and GLOW does not, so keep them on their own schedule and inject GLOW whenever suits.
Collagen stimulation, tissue recovery, increased GH output layered on direct matrix signalling. No interaction concerns; the GH secretagogues require fasting while the blend does not, so the two run on independent timing.
Another growth hormone peptide commonly used alongside GLOW. No interaction, but it needs a fasting schedule and GLOW does not.
GHRH analogue considered compatible; no interaction, separate fasting schedule.
Named for skin brightening, antioxidant protection, and detox support.
Skin brightening, antioxidant protection, detoxification support. GHK-Cu already carries antioxidant activity, so this is additive rather than gap-filling.
Layered on top through topical use to add wrinkle reduction. They work on facial muscle signalling rather than on the skin's structure, so they do a different job.
Topical layering for wrinkle reduction. Neuromuscular-signalling peptides acting on dynamic expression lines, mechanistically non-overlapping with matrix remodelling.
Suggested to help reduce stubborn fat while preserving skin elasticity during body recomposition.
Stubborn fat reduction with preservation of skin elasticity during recomposition — the dermal arm offsetting laxity that fat loss can expose.
- GLP-1 agonists (retatrutide, semaglutide, tirzepatide)
No interaction concerns and completely different mechanisms, so the two can run at the same time without timing conflicts. GLOW may help support skin elasticity and tissue quality during large weight loss, which is a common worry on these drugs.
No interaction concerns; mechanistically unrelated; no timing conflict. The blend may support tissue quality and skin elasticity during significant GLP-1-driven weight loss.
- Testosterone replacement therapy
No interaction concerns. Can be run alongside TRT without issues.
No interaction concerns; runs alongside TRT without adjustment.
A GHK-Cu cream for localised skin work alongside the injections. Topical GHK-Cu works on the surface over 8 to 16 weeks; injections reach deeper tissue and tend to show results faster, in 2 to 8 weeks. Topical use has no reported side effects and is the fallback if injections cannot be tolerated.
Localised dermal enhancement layered on systemic GLOW. Topical GHK-Cu acts at the application site over 8 to 16 weeks; injectable reaches muscle, tendon, ligament, and organ tissue with results in 2 to 8 weeks. Topical is also the salvage route if parenteral copper proves intolerable.
The four-peptide version of this blend — the same three plus 10 mg of KPV, a strong anti-inflammatory peptide. Choose KLOW over GLOW if you have gut inflammation, autoimmune-related inflammation, or long-term body-wide inflammation, or if you want extra calming of the copper injection reaction. If your concern is injury recovery and skin quality without major inflammation, GLOW covers it.
Adds KPV 10 mg, an alpha-MSH-derived tripeptide that inhibits NF-kB activation and reduces pro-inflammatory cytokines. Indicated over GLOW for gut inflammation, autoimmune-related inflammation, chronic systemic inflammation, or additional mast cell stabilisation to further reduce GHK-Cu injection site reactions.
The stripped-down healing combination at 5 mg each. GLOW doubles both to 10 mg and adds 50 mg of GHK-Cu. If the goal is purely healing muscles, tendons, and ligaments and skin does not matter, the Wolverine Stack is the cheaper choice.
BPC-157 5 mg + TB-500 5 mg — tissue repair without the collagen, dermal, and gene expression layer of GHK-Cu. GLOW doubles each healing component to 10 mg and adds GHK-Cu 50 mg; for purely musculoskeletal goals the Wolverine Stack is the more cost-effective option.
Common questions
Why not just run BPC-157, TB-500, and GHK-Cu separately?
You can. The blend exists for convenience: one vial, one injection, one protocol instead of three of each. The peptides do not interact badly when combined. The trade-off is that you cannot change the dose of one without changing the others.
Separate administration is viable. The blend consolidates three reconstitutions, injections, and storage considerations into one, and the components do not interact negatively. The cost is loss of independent titration at the fixed 5:1:1 ratio.
Will the GHK-Cu make the injection burn?
It can. GHK-Cu carries a positive charge and makes immune cells at the injection site release histamine, causing redness, swelling, and burning. In the blend, BPC-157's anti-inflammatory action helps calm this, and most users report less burning than with GHK-Cu on its own. Inject slowly, let the solution reach room temperature, and rotate sites to reduce it further.
GHK-Cu is cationic and triggers mast cell degranulation with local histamine release. In the blend, BPC-157's suppression of COX-2 and inflammatory cytokines likely moderates the response; most users report less burning and erythema than standalone GHK-Cu. Slow injection, room-temperature solution, and site rotation further reduce it.
Does the blue or green colour mean something is wrong?
No. The colour comes from the copper in GHK-Cu and is normal. Do not use it if it looks cloudy, has particles floating in it, or has changed from blue-green to something else entirely.
No. The tint is the copper in GHK-Cu. Discard if the solution is cloudy, contains particulates, or has shifted away from its normal blue-green.
Can it be injected anywhere, or does it need to be near an injury?
TB-500 works throughout the body wherever you inject it. BPC-157 clears quickly, so it works best near the damaged tissue. GHK-Cu works body-wide but also locally. If you have a specific injury, inject near it; for general skin and anti-ageing use, anywhere under the skin works. Common sites are the abdomen, thigh, or upper arm.
TB-500 distributes systemically regardless of site. BPC-157, with a sub-30 minute half-life, is most effective near damaged tissue. GHK-Cu provides systemic gene expression effects with additional localised benefit. Inject near a specific injury to maximise local BPC-157 concentration; for anti-ageing use, any subcutaneous site — abdomen, thigh, upper arm — is suitable.
How does GLOW compare to topical GHK-Cu?
Creams and serums work on the skin surface where you apply them, improving texture, wrinkles, and elasticity over 8 to 16 weeks. Injected GHK-Cu reaches deeper tissues — muscle, tendon, ligament, organs — and results tend to appear faster, in 2 to 8 weeks. GLOW delivers GHK-Cu by injection.
Topical GHK-Cu acts at the application site over 8 to 16 weeks. Injectable GHK-Cu reaches muscle, tendon, ligament, and organ tissue inaccessible to topical delivery, with results typically in 2 to 8 weeks. GLOW delivers GHK-Cu systemically by subcutaneous injection.
Does it need to be cycled?
Yes. BPC-157 and TB-500 are best used when tissue is damaged and stopped once healing is done. Standard runs are 4 to 8 weeks for active healing, extendable to 8 to 12 weeks for deeper repair. GHK-Cu can run longer, 8 to 16 weeks, for anti-ageing. A 4 to 6 week break between cycles is standard practice.
BPC-157 and TB-500 are reactionary compounds — used during tissue damage and discontinued once healing is achieved. Standard runs are 4 to 8 weeks, extendable to 8 to 12 weeks for deeper repair. GHK-Cu tolerates 8 to 16 week runs for anti-ageing. A 4 to 6 week inter-cycle break is standard practice.
Is there any study of the three together?
No. Each peptide has its own research, but no published study has tested this three-peptide combination or shown that they work better together. To be honest, the combined effect could be more, equal to, or less than expected.
No. No published study has examined the combination or tested synergy. The rationale is mechanistic — non-overlapping pathways across repair phases — and the combined effect could be additive, synergistic, or less than expected.
References
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.
- McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025.
- Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780.
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.
- Bock-Marquette I, et al. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair. Nature. 2004;432(7016):466-472.
- Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229.
- Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987.
- Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376.
- Pickart L, et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108.
This entry has been reviewed and expanded with additional reference material. Units are recomputed from the stated protocol.